Evidence map›Paper›PMID 40550740›Full record

ArticleACS chemical neuroscience2025

Machine Learning Model for Predicting Sertraline-like Activities and Its Impact on Cancer Chemosensitization.

Jin-Yu Xia, Ze-Yu Sun, Ying Xue, Ying-Qian Zhang, Zhi-Wei Feng, Yu-Long Li

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jin-Yu XiaSchool of Civil Engineering, College of Chemistry and Environmental Engineering, Sichuan University of Science and Engineering, Zigong 643000, P. R. China.
Ze-Yu SunDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID 0009-0002-3227-8923
Ying XueDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Ying-Qian ZhangSchool of Civil Engineering, College of Chemistry and Environmental Engineering, Sichuan University of Science and Engineering, Zigong 643000, P. R. China.
Zhi-Wei FengDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID 0000-0001-6533-8932
Yu-Long LiSchool of Civil Engineering, College of Chemistry and Environmental Engineering, Sichuan University of Science and Engineering, Zigong 643000, P. R. China.ORCID 0000-0002-5579-3269

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective serotonin reuptake inhibitors (SSRIs) like sertraline are crucial in treating depression and anxiety disorders, and studies indicate their potential as chemosensitizers in cancer therapy. This research develops a machine-learning predictive model to identify novel compounds with sertraline-like antidepressant activity. We constructed and validated a customized machine-learning model to predict SSRI activity in new compounds. By applying feature engineering to the chemical structures and bioactivity data of sertraline and its analogs, we trained multiple machine-learning algorithms. Through extensive comparative analysis, we found that the support vector machine (SVM) model demonstrated exceptional performance, achieving an accuracy rate of up to 93%. By further optimizing and integrating the SVM model, we successfully enhanced its accuracy, reaching an impressive 95% capability in predicting more active SSRI compounds. This study successfully developed a targeted, rapid, and efficient machine learning model capable of accurately predicting SSRI activity. The model serves as a valuable tool for rapidly screening novel SSRI drug candidates with superior activity, bringing immense value to the field of drug development.

Indexed as

Antineoplastic AgentsMachine LearningNeoplasmsSelective Serotonin Reuptake InhibitorsSertralineAntidepressive AgentsHumansSupport Vector MachineAntidepressive AgentsAntineoplastic AgentsSelective Serotonin Reuptake InhibitorsSertralinedrug discoveryescitalopram analogsfeature engineeringmachine learningpredictive modelSSRI activity prediction

Identifiers

PMID40550740
PMCPMC12371727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.